Your browser doesn't support javascript.
loading
Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
van der Noord, Vera E; van der Stel, Wanda; Louwerens, Gijs; Verhoeven, Danielle; Kuiken, Hendrik J; Lieftink, Cor; Grandits, Melanie; Ecker, Gerhard F; Beijersbergen, Roderick L; Bouwman, Peter; Le Dévédec, Sylvia E; van de Water, Bob.
Afiliação
  • van der Noord VE; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
  • van der Stel W; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
  • Louwerens G; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
  • Verhoeven D; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
  • Kuiken HJ; Division of Molecular Carcinogenesis, The NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lieftink C; Division of Molecular Carcinogenesis, The NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Grandits M; Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
  • Ecker GF; Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
  • Beijersbergen RL; Division of Molecular Carcinogenesis, The NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bouwman P; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
  • Le Dévédec SE; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
  • van de Water B; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands. b.water@lacdr.leidenuniv.nl.
Breast Cancer Res ; 25(1): 51, 2023 05 05.
Article em En | MEDLINE | ID: mdl-37147730
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article